FY2026 EPS Forecast for Urogen Pharma Boosted by Analyst

Urogen Pharma (NASDAQ:URGN) – Stock analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Urogen Pharma in a note issued to investors on Thursday, November 5th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.77) for the year, up from their prior estimate of ($0.83). HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2026 earnings at $0.02 EPS, Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.21 EPS, Q4 2027 earnings at $0.28 EPS and FY2027 earnings at $0.59 EPS.

Other equities research analysts have also recently issued research reports about the stock. TD Cowen increased their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. UBS Group reissued an “outperform” rating on shares of Urogen Pharma in a report on Thursday, November 5th. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $56.00 price target on shares of Urogen Pharma in a research note on Thursday, September 10th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $53.38.

Urogen Pharma Price Performance

NASDAQ URGN opened at $25.32 on Monday. Urogen Pharma has a 1-year low of $16.50 and a 1-year high of $50.81. The stock has a 50-day moving average of $38.08 and a 200-day moving average of $31.59.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.14). The firm had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million.

Insiders Place Their Bets

In other Urogen Pharma news, CFO Chris Degnan sold 2,202 shares of the business’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the transaction, the chief financial officer owned 4,561 shares of the company’s stock, valued at approximately $167,343.09. The trade was a 32.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total transaction of $37,383.32. Following the transaction, the insider owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 65,269 shares of company stock valued at $3,037,646. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Urogen Pharma during the second quarter valued at approximately $117,814,000. Jefferies Financial Group Inc. purchased a new stake in Urogen Pharma during the second quarter valued at $80,947,000. Opaleye Management Inc. increased its position in Urogen Pharma by 0.7% during the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock valued at $52,992,000 after acquiring an additional 9,996 shares during the last quarter. Bank of America Corp DE purchased a new stake in Urogen Pharma during the second quarter valued at $17,506,000. Finally, Rice Hall James & Associates LLC bought a new position in Urogen Pharma in the second quarter valued at about $11,064,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.